Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3

Published:2019-04 Issue: Volume:302 Page:101-107
ISSN:0009-2797
Container-title:Chemico-Biological Interactions
language:en
Short-container-title:Chemico-Biological Interactions

Author:

Bukum Neslihan,Novotna Eva,Morell Anselm,Hofman Jakub,Wsol Vladimir

Funder

Czech Science Foundation

Agency of Charles University

EFSA-CDN

InoMed project

the European Union

Charles University

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference70 articles.

1. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy;Soverini;Mol. Canc.,2018

2. Treatment of advanced non-small cell lung cancer in the era of targeted Therapy;Masri;Curr. Pulmonol. Rep.,2018

3. Innovative strategies: targeting subtypes in metastatic breast cancer;Pegram;Am. Soc. Clin. Oncol. Educ. Book,2018

4. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination;Yu;Development,2016

5. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling;Chaussade;Biochem. J.,2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adipocyte maturation impacts daunorubicin disposition and metabolism;European Journal of Clinical Investigation;2024-09-10

2. AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications;ACS Medicinal Chemistry Letters;2024-07-03

3. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment;Journal of Medicinal Chemistry;2023-07-06

4. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer;European Journal of Medicinal Chemistry;2023-02

5. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters;Archives of Toxicology;2022-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3